Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager molecules, which use patient's immune cells to destroy tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Affimed reports Q1 loss, positive clinical data in cancer treatments

Affimed's Q1 2024 performance showed a net loss but highlighted positive clinical data and progress in cancer treatments.
Despite enrollment delays in the LuminICE trial, Affimed's programs leveraging the innate immune system demonstrate consistency and success.
Addressing financial challenges, patient enrollment issues, and leveraging opportunities in future study phases and partnerships are key for Affimed's growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Affimed NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of cancer immunotherapies. The company’s proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. It operates through the Germany and USA geographical segments. The company was founded in 2000 and is headquartered in Mannheim, Germany.

HEIDELBERG, Germany, April 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided the final results from its phase 2 REDIRECT study investigating its innate cell engager (ICE®) AFM13 monotherapy in patients with heavily pretreated advanced-stage r/r PTCL. The results are being presented at the American Association for Cancer Research (AACR) Annual Meeting by Dr. Won Seog Kim, Professor of Hematology-Oncology at Samsung Medical Center in Seoul and a principal investigator for the study, and establishes that AFM13 monotherapy showed efficacy in the treatment of relapsed/refractory peripheral T cell lymphoma (r/r PTCL) patients with a differentiated safety profile.

Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023

HEIDELBERG, Germany, April 06, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 4, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”).

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

HEIDELBERG, Germany, March 29, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that the first patient was dosed in a phase 1 multicenter, open label, first-in-human dose escalation study of the innate cell engager (ICE®) AFM28 monotherapy in patients with CD123-positive relapsed/refractory (r/r) acute myeloid leukemia (AML). AFM28 efficiently directs natural killer (NK) cells to CD123-positive leukemic cells, including blasts and leukemic stem and progenitor cells, inducing their depletion in samples of patients with AML and myelodysplastic syndrome (MDS).

Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

Affimed N.V. (NASDAQ:AFMD ) Q4 2022 Earnings Conference Call March 23, 2023 8:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Smith - Chief Financial Officer Wolfgang Fischer - Chief Operating Officer Conference Call Participants Daina Graybosch - SVB Securities Srikripa Devarakonda - Truist Maurice Raycroft - Jefferies Li Watsek - Cantor Operator Good day, ladies and gentlemen.

Affimed N.V. (AFMD) Q4 2022 Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -15.79% and 45.75%, respectively, for the quarter ended December 2022.

Affimed N.V. (AFMD) Reports Q4 Loss, Tops Revenue Estimates

HEIDELBERG, Germany, March 23, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.

Affimed Reports 2022 Financial Results and Operational Progress

HEIDELBERG, Germany, March 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release full year 2022 results and corporate update on Thursday, March 23, 2023. The Company will host a conference call at 8:30 a.m. EDT / 13:30 CET.

Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

HEIDELBERG, Germany, March 14, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that two abstracts with clinical and preclinical data on AFM13, its anti-CD30 targeting innate cell engager (ICE ® ), have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research (AACR), taking place April 14-19, 2022 in Orlando, Florida.

Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for C

PLZEN, Czech Republic, March 09, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has successfully completed the technology development activities specified under the terms of its research grant entitled “Research and development of a unique biotechnology for the isolation of antibodies with a therapeutic effect”. Under the grant, awarded to AbCheck by the Ministry of Industry and Trade of the Czech Republic in 2019, the Company has received a total of more than €1 million.

AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery

HEIDELBERG, Germany, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will participate in a fireside chat at the H.C. Wainwright Cell Therapy Conference on Tuesday, February 28, 2023, at 8:30 a.m. EST / 14:30 CET.

Affimed to Participate in Fireside Chat at the H.C. Wainwright Cell Therapy Virtual Conference

PLZEN, Czech Republic, Feb. 21, 2023 (GLOBE NEWSWIRE) -- AbCheck s.r.o., a technology company delivering disruptive antibody discovery and development solutions for challenging targets, announced today that it has entered into a collaboration with a biotech company developing antibodies targeting peripheral neural response, funded by a top-tier European Venture Capital firm.

AbCheck Announces Collaboration to Apply Microfluidics Technology to the Discovery of Antibodies Against Challenging Therapeutic Neurology Target

HEIDELBERG, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today its Chief Executive Officer, Dr. Adi Hoess, will present at the SVB Securities 2023 Global Biopharma Conference on Tuesday, February 14, 2023 at 2:20 p.m. EST / 20:20 CET.

Affimed to Present at the SVB Securities 2023 Global Biopharma Conference

BioAtla, Inc

Eiger BioPharmaceuticals

Gracell Biotechnologies

Immuneering Corp

Nkarta, Inc.

Instil Bio

Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.

7 Cheap But Risky Biotech Stocks

HEIDELBERG, Germany, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has issued a written response to the Company's pre-IND meeting request for the AFM13 and Artiva Biotherapeutics, Inc. (“Artiva”)'s AB-101 co-administered combination therapy in relapsed/refractory (r/r) Hodgkin lymphoma (HL) and the exploratory arm evaluating the combination in r/r CD30-positive peripheral T-cell lymphoma (PTCL). Based on the written response, Affimed remains on track to submit an IND in the first half of 2023 and, subject to FDA clearance of the IND, to initiate a clinical study during 2023.

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

HEIDELBERG, Germany, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that the ANSM has authorized a CTA for the phase 1 study of AFM28 (AFM28-101) in relapsed/refractory acute myeloid leukemia (AML).

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

Affimed N.V. (AFMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Here's Why Affimed N.V. (AFMD) is Poised for a Turnaround After Losing 47.1% in 4 Weeks

HEIDELBERG, Germany, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster highlighting new preclinical data for its Innate Cell Engager (ICE®) AFM28 targeting CD123 and CD16A at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, Louisiana.

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 M

HEIDELBERG, Germany, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced topline data from its phase 2 REDIRECT study investigating AFM13 monotherapy in patients with advanced-stage r/r PTCL.

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

HEIDELBERG, Germany, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today provided a data update from the ongoing phase 1/2 study of the Company's lead innate cell engager (ICE®) AFM13 precomplexed with cord blood-derived natural killer (cbNK) cells in patients with CD30-positive relapsed or refractory Hodgkin and Non-Hodgkin lymphomas. The results are being presented today at the 64th American Society of Hematology (ASH) Annual Meeting by principal investigator Yago Nieto, M.D., Ph.D., Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center. Results from the study continue to demonstrate high objective and complete response rates with a well-tolerated safety profile.

Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting

HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will host an Investor Event on December 10 during the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA.

Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting

The clinical-stage biotech focuses on immuno-oncology therapies.

Why Shares of Affimed Fell Thursday

Affimed N.V. (NASDAQ:AFMD ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Alex Fudukidis - Director of IR Adi Hoess - CEO Andreas Harstrick - Chief Medical Officer Arndt Schottelius - Chief Scientific Officer Wolfgang Fischer - COO Angus Smith - CFO Conference Call Participants Srikripa Devarakonda - Truist Maurice Raycroft - Jefferies Daina Graybosch - SVB Securities Do Kim - Piper Sandler Li Watsek - Cantor James Shin - Wells Fargo Yale Jen - Laidlaw & Company Zhiqiang Shu - Berenberg Operator Thank you for standing by.

Affimed N.V. (AFMD) Q3 2022 Earnings Call Transcript

Affimed N.V. (AFMD) delivered earnings and revenue surprises of 42.11% and 96.03%, respectively, for the quarter ended September 2022.

Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates

HEIDELBERG, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the third quarter ended September 30, 2022 and provided an update on clinical and corporate progress.

News for Affimed Stock (AFMD)